Stock news: Defence Therapeutics facing collaborations

After years of hype, the prices of the best-known biotech shares have also fallen recently. The Canadian cancer hopeful Defence Therapeutics (ISIN: CA24463V1013) has also lost ground in recent months. Yet the Company is on a strong course. Defence Therapeutics has patented Accum, a technology for drug conjugates, which it also uses for vaccinations. Two Phase 1 trials are scheduled to start against breast and skin cancer this year. In addition, Defence Therapeutics has another iron in the fire with a vaccine against human papillomavirus (HPV). As Defence CEO Sébastien Plouffe points out, some major industry players are already showing interest in collaborations. An update.

Den vollständigen Artikel lesen ...